Zero Candida Begins Prototype Production of AI-Enabled Therapeutic Device ZC-001
Zero Candida Technologies, Inc. has completed the design freeze and started prototype production of its ZC-001 therapeutic device, announced in a press release. The company will produce 50 prototype units, expected to be completed by the first quarter of 2026.
The ZC-001 device integrates blue light therapy, targeted drug delivery, and wireless diagnostics to provide personalized treatment for Vulvo-Vaginal Candidiasis (VVC). The design freeze finalizes specifications for both the device and its SMART docking and charging case.
Key features include a docking system for automatic alignment and sterilization, wireless connectivity for encrypted data transfer, light indicators for user feedback, and medical-grade materials for comfort and biocompatibility. The device is designed for at-home use with real-time data transmission to enable physician monitoring and AI-driven analytics.
According to the company, the modular design of ZC-001 will support scalable manufacturing and potential adaptation for other gynecologic applications.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
XtalPi Launches Kodexia siRNA Discovery Platform
XtalPi Advances Hair Loss Drug Into IND Enabling Studies
CureMD Earns ISO/IEC 42001 Certification for AI Management
Vuzix to Show Causeway Optical Interconnect Platform for AI Data Centers
AbbVie Partners With Valkai on AI Tools for Clinical Development
Daily AI Brief: the AI news that matters, in your inbox.